Journal Browser

► Journal Browser

Editors

Topical Collection Information

Dear Colleagues,

Reducing breast cancer risk through targeted screening, treatment advances, and novel research efforts is the key focus of this Topical Collection on “Progress in Breast Cancer Diagnosis and Treatment”. We are also interested in manuscripts aimed at improving the quality of life of breast cancer patients and survivors. In this regard, research topics include, but are not limited to, lifestyle factors and habits such as nutrition, exercise, and weight control, as well as supportive care.

Of particular interest to this Topical Collection is research pertaining to circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA). Such research may offer a less-expensive and non-invasive means for predicting disease severity and survival potential in breast cancer patients. Submissions focusing on evolving therapies (e.g., atezolizumab, nab-paclitaxel, ipatasertib, capivasertib, and bicalutamide) also are welcome.

Prof. Dr. Jimmy T. Efird
Dr. Tithi Biswas
Collection Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the collection website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

breast cancer
TNBC
ER-positive tumors
HER2-positive tumors
inflammatory breast cancer
novel therapies
breast cancer survival
health promotion
lifestyle behaviors and habits
epidemiology of breast cancer

Published Papers (3 papers)

Download All Papers

2023

Jump to: 2022

Open AccessArticle

A Hypofractionated Radiotherapy Schedule with a Simultaneous Integrated Boost for Breast Cancer: Outcomes including Late Toxicity and Health Quality

and

Medicina 2023, 59(4), 675; https://doi.org/10.3390/medicina59040675 - 29 Mar 2023

Viewed by 625

Abstract

Introduction: This study aimed to evaluate the long-term adverse effects on the physical appearance and overall well-being of breast cancer patients who receive hypofractionated radiotherapy as whole breast and simultaneous integrated boost (SIB) treatment, utilizing intensive modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT), or a hybrid therapy approach. Material/Methods: This investigation involved administering hypofractionated SIB-VMAT therapy to individuals diagnosed with early-stage breast cancer. Treatment was carried out over a three-week period in which a total dose of 48.06 Gy was given to the entire breast and 54 Gy was given to the tumor bed. Data on skin toxicity and cosmetic outcomes were analyzed both during the acute phase and during the three-month and five-year follow-up periods after treatment. Results: A total of 125 patients treated between December 2014 and December 2016 were included in the study. The data of these patients with at least 5 years of follow-up were analyzed. Conclusions: Considering these long-term results, hypofractionated SIB-VMAT can be considered a viable treatment choice, even for patients with unfavorable conditions. Full article

2022

Jump to: 2023

Open AccessReview

Molecular Pathways Related to Sulforaphane as Adjuvant Treatment: A Nanomedicine Perspective in Breast Cancer

María Zenaida Saavedra-Leos

Euclides Jordan-Alejandre

Jonathan Puente-Rivera

and

Macrina Beatriz Silva-Cázares

Medicina 2022, 58(10), 1377; https://doi.org/10.3390/medicina58101377 - 01 Oct 2022

Cited by 4 | Viewed by 1317

Abstract

Because cancer is a multifactorial disease, it is difficult to identify the specific agents responsible for the disease’s progression and development, but lifestyle and diet have been shown to play a significant role. Diverse natural compounds are demonstrating efficacy in the development of novel cancer therapies, including sulforaphane (1-isothiocyanate-4-(methylsulfinyl)butane), a compound found in broccoli and other cruciferous vegetables that promotes key biological processes such as apoptosis, cell cycle arrest, autophagy, and suppression of key signalling pathways such as the PI3K/AKT/mTOR pathway in breast cancer cells. However, one of the primary challenges with sulforaphane treatment is its low solubility in water and oral bioavailability. As a consequence, several investigations were conducted using this component complexed in nanoparticles, which resulted in superior outcomes when combined with chemotherapy drugs. In this study, we discuss the properties and benefits of sulforaphane in cancer therapy, as well as its ability to form complexes with nanomolecules and chemotherapeutic agents that synergize the antitumour response in breast cancer cells. Full article

► Show Figures